Search clinical trials for: [C14]AZD9668

Total 2116 results

AstraZeneca

Completed

Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers (ADME)

Healthy

United Kingdom
AstraZeneca

Completed

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis (INCA)

Cystic Fibrosis

Sweden, Russian Federation, United Kingdom, Poland, Denmark, Germany
AstraZeneca

Completed

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Germany, Philippines, Ukraine, Japan, United States, Australia, Canada, Slovakia, Taiwan, Russian Federation
AstraZeneca

Completed

AZD9668 Relative Bioavailability

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Completed

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

Healthy

United Kingdom
AstraZeneca

Completed

AZD9668 Relative Bioavailability

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Completed

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis (NEPAL)

Bronchiectasis

United Kingdom, Canada
AstraZeneca

Completed

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Romania, Ukraine, Denmark, Netherlands, Canada
AstraZeneca

Completed

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Withdrawn

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

Pharmacokinetics | Pharmacodynamics

Sweden
Oxford University Hospitals NHS Trust
University of Oxford; Cancer Research UK; National Institute for Health Research...

Completed

Phase 1 Trial of CXD101 in Patients With Advanced Cancer

Advanced Cancer

United Kingdom
AstraZeneca

Completed

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy

United States
AstraZeneca

Completed

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

Type 2 Diabetes

United States
AstraZeneca

Terminated

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects (JSMAD)

Healthy

United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Czech Republic, Poland, Hungary, Romania, Slovakia
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
AstraZeneca

Completed

Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers (JMAD)

Healthy

Japan
National Taiwan University Hospital

Recruiting

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection

H. Pylori Infection

Taiwan
AstraZeneca

Completed

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

Healthy

Sweden
AstraZeneca

Completed

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

Healthy Volunteer

United States
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
Implicit Bioscience
Royal Brisbane and Women's Hospital

Completed

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Implicit Bioscience

Withdrawn

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome
TNO
Netherlands: Ministry of Health, Welfare and Sports

Completed

Body Fat Distribution and Fat Metabolism

Obesity | Metabolic Disease

Netherlands
Implicit Bioscience

No longer available

Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

COVID | SARS-CoV2 | ARDS, Human | Ards

Italy
Cognition Therapeutics
National Institute on Aging (NIA)

Completed

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects (COG0108)

Alzheimer Disease

United States
Implicit Bioscience

Withdrawn

IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Australia
AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

Solid Tumours

United Kingdom
National Institute of Allergy and Infectious Diseases...
PPD; University of Washington; Vanderbilt University Medical Center; Implicit Bioscience

Terminated

COVID-19 and Anti-CD14 Treatment Trial (CaTT)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)

United States
Biotie Therapies Inc.
PRA Health Sciences; Tandem Labs; Xceleron Inc

Completed

Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant

N/A, as Healthy Volunteers

Netherlands
TYK Medicines, Inc

Recruiting

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Healthy Volunteers

China
Theravance Biopharma

Completed

TD-1211 IV/Oral Mass Balance Study

OIC

United States
University of Wisconsin, Madison
National Eye Institute (NEI)

Recruiting

Moderators and Mediators of Perceptual Learning

Cognitive Change

United States
Fudan University

Recruiting

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Breast Cancer

China
The Netherlands Cancer Institute
Leiden University Medical Center; University Medical Center Nijmegen

Recruiting

Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1)

Soft Tissue Sarcoma Adult

Netherlands
AstraZeneca

Completed

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

United Kingdom
Shire

Completed

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Hereditary Angioedema

United States
CSL Behring

Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Antibody-mediated Rejection

United States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
Kowa Research Institute, Inc.

Completed

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

Dyslipidemia

United States
IMMUNOe Research Centers

Completed

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

CVI - Common Variable Immunodeficiency

United States
CSL Behring

Completed

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Germany, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
Shire

Completed

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Graft Rejection

United States, Germany
CSL Behring
Chiltern International Inc.

Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

Includes: Hereditary Angioedema

United States, Denmark, Germany, Switzerland
Stanley Jordan, MD
CSL Behring

Completed

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Kidney Transplantation

United States
CSL Behring

Completed

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Hereditary Angioedema

United States, Canada
Radboud University Medical Center

Completed

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia (VECTOR)

Inflammation | Endotoxemia | Multi Organ Dysfunction Syndrome

Netherlands
AstraZeneca
Parexel

Completed

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Advanced Malignancies

United Kingdom, United States

3

Subscribe